Cipla Limited (CIPLA.NS)
NSE - NSE Real-time price. Currency in INR
Add to watchlist
At close: 03:29PM IST
| Previous close | 971.30 |
| Open | 980.75 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 921.85 - 986.70 |
| 52-week range | 738.10 - 1,005.00 |
| Volume | |
| Avg. volume | 2,420,631 |
| Market cap | 748.819B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 28.96 |
| EPS (TTM) | 32.05 |
| Earnings date | 25 Jan 2022 |
| Forward dividend & yield | 5.00 (0.51%) |
| Ex-dividend date | 09 Aug 2021 |
| 1y target est | 1,063.49 |
- PR Newswire
Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).
- PR Newswire
Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL)
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).
© 2021 Yahoo. All rights reserved.
